Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managin...

Podrobná bibliografie
Hlavní autoři:	Giorgio Walter Canonica, Francesco Blasi, Pierluigi Paggiaro, Gianenrico Senna, Giovanni Passalacqua, Antonio Spanevello, Stefano Aliberti, Diego Bagnasco, Marco Bonavia, Matteo Bonini, Luisa Brussino, Caterina Bucca, Maria F. Caiaffa, Cecilia Calabrese, Gianna Camiciottoli, Marco Caminati, Giovanna E. Carpagnano, Cristiano Caruso, Stefano Centanni, Maria E. Conte, Angelo G. Corsico, Lorenzo Cosmi, Maria T. Costantino, Nunzio Crimi, Simona D’Alò, Maria D'Amato, Stefano Del Giacco, Alessandro Farsi, Elisabetta Favero, Maria P. Foschino Barbaro, Gabriella Guarnieri, Giuseppe Guida, Manuela Latorre, Salvatore Lo Cicero, Carlo Lombardi, Luigi Macchia, Francesco Mazza, Francesco Menzella, Manlio Milanese, Marcello Montagni, Paolo Montuschi, Eleonora Nucera, Roberta Parente, Vincenzo Patella, Girolamo Pelaia, Laura Pini, Francesca Puggioni, Luisa Ricciardi, Fabio L.M. Ricciardolo, Luca Richeldi, Erminia Ridolo, Giovanni Rolla, Pierachille Santus, Nicola Scichilone, Giuseppe Spadaro, Andrea Vianello, Vittorio Viviano, Mona R. Yacoub, Maria C. Zappa, Enrico Heffler
Médium:	Článek
Jazyk:	English
Vydáno:	Elsevier 2020-10-01
Edice:	World Allergy Organization Journal
Témata:	Severe asthma Biologics Oral corticosteroids Real-life Registr
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S1939455120303677

Podobné jednotky

Patient and physician perspectives on biological treatment in severe asthma: a Severe Asthma Network Italy survey
Autor: Claudia Crimi, a další
Vydáno: (2023-11-01)

Economic impact of a more extensive use of FENO testing on the Italian population with asthma
Autor: Carla Rognoni, a další
Vydáno: (2023-06-01)

Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center
Autor: Paolo Solidoro, a další
Vydáno: (2022-01-01)

Critical evaluation of asthma biomarkers in clinical practice
Autor: Giuseppe Guida, a další
Vydáno: (2022-10-01)

Nasal polyps impact in severe asthma patients: evidences from the SANI
Autor: Giorgio Walter Canonica, a další
Vydáno: (2020-08-01)

Asthma severity: the patient’s point of view
Autor: Gabriella Guarnieri, a další
Vydáno: (2024-12-01)

Is Bronchiectasis (BE) Properly Investigated in Patients with Severe Asthma? A Real-Life Report from Eight Italian Centers
Autor: Giovanna Elisiana Carpagnano, a další
Vydáno: (2023-10-01)

Severe asthma: One disease and multiple definitions
Autor: Diego Bagnasco, MD, PhD, a další
Vydáno: (2021-11-01)

Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort
Autor: Marco Caminati, MD, a další
Vydáno: (2024-08-01)

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders
Autor: Diego Bagnasco, a další
Vydáno: (2023-08-01)

Phenotype overlap in the natural history of asthma
Autor: Fabio L.M. Ricciardolo, a další
Vydáno: (2023-05-01)

Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study
Autor: Paolo Solidoro, a další
Vydáno: (2019-04-01)

Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
Autor: Alessandra Vultaggio, a další
Vydáno: (2023-05-01)

Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies
Autor: Giorgio Walter Canonica, a další
Vydáno: (2021-09-01)

Biologics as well as inhaled anti-asthmatic therapy achieve clinical remission: Evidence from the Severe Asthma Network in Italy (SANI)
Autor: Giorgio Walter Canonica, MD, a další
Vydáno: (2025-01-01)

Tezepelumab: patient selection and place in therapy in severe asthma
Autor: Francesco Menzella, a další
Vydáno: (2024-04-01)

Treatment strategies for asthma: reshaping the concept of asthma management
Autor: Alberto Papi, a další
Vydáno: (2020-08-01)

Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis
Autor: Maria D'Amato, a další
Vydáno: (2022-05-01)

Omalizumab as add‐on therapy in a patient with severe asthma and OSA
Autor: Giulia Scioscia, a další
Vydáno: (2020-03-01)

Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps
Autor: Corrado Pelaia, a další
Vydáno: (2023-03-01)

Efficacy of Mepolizumab in patients with previous Omalizumab treatment failure: real life observation
Autor: Diego Bagnasco, a další
Vydáno: (2020-08-01)

The evidence on tiotropium bromide in asthma: from the rationale to the bedside
Autor: Dejan Radovanovic, a další
Vydáno: (2017-05-01)

Vascular remodeling and TSLP/angiogenin overexpression in severe mixed asthma
Autor: Francesca Bertolini, a další
Vydáno: (2025-02-01)

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
Autor: Erminia Ridolo, a další
Vydáno: (2020-10-01)

Erratum to: The evidence on tiotropium bromide in asthma: from the rationale to the bedside
Autor: Dejan Radovanovic, a další
Vydáno: (2017-06-01)

Is it severe asthma or asthma with severe comorbidities?
Autor: Brussino L, a další
Vydáno: (2017-11-01)

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
Autor: Giovanna Elisiana Carpagnano, a další
Vydáno: (2021-03-01)

Positioning tezepelumab for patients with severe asthma: from evidence to unmet needs
Autor: Carlo Lombardi, a další
Vydáno: (2024-11-01)

The extracellular matrix of the lung and airway responsiveness in asthma
Autor: F.G. Salerno, a další
Vydáno: (2016-01-01)

Very long-term data on patients with severe eosinophilic asthma treated with mepolizumab: a case series
Autor: Carlo Lombardi, a další
Vydáno: (2024-07-01)

Alexithymia and asthma: a systematic review
Autor: Orlando Silvestro, a další
Vydáno: (2023-08-01)

Interleukin-5 in the Pathophysiology of Severe Asthma
Autor: Corrado Pelaia, a další
Vydáno: (2019-12-01)

Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study
Autor: Giorgio Walter Canonica, a další
Vydáno: (2018-11-01)

Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab
Autor: Carpagnano GE, a další
Vydáno: (2019-03-01)

Introduction of the telemonitoring device Turbo+ in the management of patients suffering from asthma in Italy: a budget impact analysis
Autor: Filippo Rumi, a další
Vydáno: (2022-04-01)

Comparison between clinical trials and real-world evidence studies on biologics for severe asthma
Autor: Francesco Menzella, a další
Vydáno: (2022-11-01)

Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis
Autor: Cristiano Caruso, a další
Vydáno: (2022-09-01)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
Autor: Andrea Portacci, a další
Vydáno: (2023-10-01)

Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab
Autor: Andrea Giovanni Ledda, a další
Vydáno: (2023-09-01)

Dupilumab in the Treatment of Severe Uncontrolled Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and Comorbid Asthma—A Multidisciplinary Monocentric Real-Life Study
Autor: Gian Luca Fadda, a další
Vydáno: (2025-02-01)